KALV

Insider Trades

Name	Value	Action	Price	Current Price
Palleiko Benjamin LDirector, Officer: CHIEF EXECUTIVE OFFICER $147k10.9k shares SellNov 24, 2025 $13.45 --
Audhya Paul K.CHIEF MEDICAL OFFICER $71k5.3k shares SellNov 24, 2025 $13.45 --
Yea ChristopherCHIEF DEVELOPMENT OFFICER $58k4.3k shares SellNov 24, 2025 $13.45 --
Piekos BrianChief Financial Officer $60k4.5k shares SellNov 24, 2025 $13.45 --
Sweeny NicoleChief Commercial Officer $51k3.8k shares SellNov 24, 2025 $13.45 --
Palleiko Benjamin LDirector, Officer: CHIEF EXECUTIVE OFFICER $120k7.3k shares SellDec 8, 2025 $16.51 --

News

businesswire.comChiesi Group Completes Acquisition of KalVista Pharmaceuticalsbusinesswire.comJun 11

zacks.comKalVista Pharmaceuticals (KALV) Upgraded to Buy: What Does It Mean for the Stock?zacks.comJun 4

fool.comKalVista's (KALV) Chief Development Officer Sells 33,800 Shares for $905,000fool.comMay 31

gurufocus.comKalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedemagurufocus.comMay 28

businesswire.comKalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedemabusinesswire.comMay 28

Trade KALV

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical firm dedicated to the discovery, development, and commercialization of small molecule protease inhibitors. These inhibitors aim to address diseases with significant unmet medical needs. The company's core therapeutic strategy centers on its pipeline of small molecule plasma kallikrein inhibitors. These are specifically engineered to combat debilitating conditions such as hereditary angioedema (HAE) and diabetic macular edema (DME), with several formulated as oral treatments. Key products in their portfolio include: KVD001, a plasma kallikrein inhibitor that has successfully concluded a Phase II clinical trial for the treatment of DME. Sebetralstat, which is currently advancing into the Phase 3 KONFIDENT trial, poised to become an oral, on-demand therapeutic option for acute HAE attacks. KVD824, another oral candidate in development for the management of HAE. A Factor XIIa oral inhibitor program, which is in its preclinical stage, targeting a specific enzyme implicated in HAE. The company's main offices are located in Cambridge, Massachusetts.

CEO: Benjamin L. Palleiko
IPO Date: Apr 9, 2015

Market Data

Open: $26.99
High: $27.00
Low: $26.98
Volume: 4.3M
Avg Volume: 3.5M
52W High: $27.00
52W Low: $9.83

Valuation

Market Cap: $1.4B
Enterprise Value: $1.5B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-83M
Revenue: $74M
Net Income: $-164M
Cash: $229M
Debt: $152M

Events

EarningsDec 3

EPS est. -0.29429